T

Stroke workspace

Evidence
Clinician-reviewed CDS · Browser-local · No identifiers · Source-linkedRead more…

This tool is educational and informational. It does not replace clinical judgment. Verify secondary stroke prevention, CHA2DS2-VASc scoring, DOAC selection, and anticoagulation timing against the cited source before acting.

Not prospectively validated. No clinical tool replaces bedside assessment.

This tool qualifies as non-device clinical decision support under the January 2026 FDA CDS guidance (21st Century Cures Act §3060). It does not acquire or analyze patient data, it displays the basis for its recommendations, it enables independent clinician review, and it is intended for use by trained healthcare professionals.

This runs entirely in your browser; we store nothing. Even so, enter only clinical data (age, vitals, exam findings) -- not names, MRNs, or other identifiers.

Tarvinder Singh, MD -- Vascular Neurologist. March 2026.

Secondary Prevention

Mechanism-specific antithrombotic selection, timing, and PFO pathway review.

AHA/ASA 2026 acute ischemic stroke guidelineGuideline anchorPost-IVT CareStroke Evidence Map

If IV thrombolysis was actually given, keep antithrombotics on hold until the 24-hour imaging gate clears hemorrhagic transformation.

Step 1: Core Stroke Context

Confirm post-stroke status and pick the mechanism. AF leads to anticoagulation, large-vessel or small-vessel to antiplatelet therapy, cryptogenic to PFO/workup pathway.

Step 1b: AF Stroke-Risk Modifiers

CHA2DS2-VASc scoring applies only when atrial fibrillation is the confirmed mechanism.

Step 2: Anticoagulant Selection

DOAC and warfarin comparison only belongs on the AF pathway. If the mechanism is non-cardioembolic, cryptogenic, or another cardiac source, keep the attention on the mechanism-specific plan instead.

Step 3: Timing and Bleeding Review

ELAN timing and HAS-BLED are AF-specific support tools here. Leave this section alone unless atrial fibrillation is the confirmed mechanism.

What To Enter Next

Core pathway

3 pending
  • Age
  • Sex
  • Stroke mechanism

Agent selection

Ready

The anticoagulant-selection modifiers are sufficiently entered.

Timing and review

1 pending
  • Review HAS-BLED modifiers
Age, sex, and stroke mechanism. AF leads to anticoagulation, cryptogenic to PFO workup, other mechanisms to antiplatelet prevention.